In a report released today, Marianne Bulot from Bank of America Securities maintained a Sell rating on Fresenius Medical Care (FMS – Research Report). The company’s shares opened today at $19.23.
According to TipRanks, Bulot is ranked #5595 out of 8710 analysts.
Fresenius Medical Care has an analyst consensus of Moderate Sell, with a price target consensus of $21.00.
The company has a one-year high of $27.72 and a one-year low of $16.37. Currently, Fresenius Medical Care has an average volume of 442.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fresenius Medical Care (FMS) Company Description:
Founded in 1996, Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis company, which provides dialysis care and related services for patients with chronic kidney failure. It also offers a variety of healthcare products, including dialysis and non-dialysis products.
Read More on FMS:
- Fresenius Medical rises 10.2%
- Fresenius Medical rises 9.5%
- Fresenius Medical price target raised to EUR 34 from EUR 33 at Morgan Stanley
- Fresenius Medical price target raised to EUR 35.40 from EUR 33 at JPMorgan
- A New Cause for Concern: Fresenius Medical Care Adds a New International Operations Risk
